•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
•
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347) and Hong Kong (HKG: 3347) stock exchanges, has forged a strategic partnership with the Beijing government. This collaboration is marked by the inauguration of the company’s North Headquarters in the capital city. Under this partnership,…
•
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the acquisition of Medical Edge Co., Ltd, a Japan-headquartered CRO. With this strategic move, Medical Edge will become a wholly-owned subsidiary of Tigermed, enhancing the company’s ability to provide high-quality mathematical statistics and electronic data solutions…
•
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with China’s Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347). This global collaboration is centered around the application of Veeva’s modern electronic data acquisition system, Vault EDC. The innovative digital solution is designed to enhance…
•
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in…